Details

Autor(en) / Beteiligte

• Lin, Chuan-Pin
• Liang, Po-Cheng
• Huang, Ching-I
• Yeh, Ming-Lun
• Hsu, Po-Yao
• Hsu, Cheng-Ting
• Wei, Yu-Ju
• Liu, Ta-Wei
• Hsieh, Ming-Yen
• Hou, Nai-Jen
• Jang, Tyng-Yuang
• Lin, Yi-Hung
• Wang, Chih-Wen
• Lin, Zu-Yau
• Chen, Shinn-Cherng
• Huang, Chung-Feng
• Huang, Jee-Fu
• Dai, Chia-Yen
• Chuang, Wan-Long
• Yu, Ming-Lung
• Schang, Luis M.

Titel

Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals

Ist Teil von

• PloS one, 2021-02, Vol.16 (2), p.e0245479-e0245479

Ort / Verlag

United States: Public Library of Science

Erscheinungsjahr

2021

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Undetectable HCV RNA 12 weeks after the end of treatment (SVR12) has been the valid efficacy endpoint in the era of direct-acting antivirals (DAAs). Its concordance with SVR4 and SVR24 and long-term durability is unknown in Taiwanese chronic hepatitis C (CHC) patients. A total of 1080 CHC patients who received all-oral DAAs and an achieved end-of-treatment virological response (EOTVR), defined as undetectable HCV RNA at the end of therapy, were consecutively enrolled. HCV RNA was monitored 4, 12, and 24 weeks after EOT. Patients who achieved SVR24, defined as undetectable HCV RNA 24 weeks after EOT, were followed annually for assessing SVR durability. Eleven (1.02%) patients experienced HCV RNA reappearance after EOT. The most frequent timing of RNA reappearance was observed at SVR4 (n = 7), followed by SVR12 (n = 3) and SVR 24 (n = 1). The positive predictive value (PPV) and negative predictive value (NPV) of SVR4 in predicting SVR12 were 99.7% and 100%, respectively, whereas the PPV and NPV of SVR12 in predicting SVR24 were 99.9% and 100%, respectively. Pyrosequencing confirmed delayed relapse rather than reinfection for the patient who had detectable HCV RNA at SVR24. Among 978 patients who achieved SVR24, after a median follow-up period of 17.3±8.2 months, the SVR durability is 100% up to a 4-year follow-up. Achievement of SVR12 provides excellent durability of HCV seroclearance after DAA therapy. On-demand HCV RNA beyond SVR12 should be recommended for patients with unexplainable abnormal liver function or high-risk behaviors.